For example, abatacept, a fully humanized fusion protein of extracellular domain of CTLA-4 and Fc fraction of IgG1, has been approved for the RA patients with inadequate response to anti-TNF therapy (Genovese et al., 2005). This evidence concerns the gene TNF and rheumatoid arthritis.